



Press release

25 September 2008

Curidium Medica Plc

("Curidium" or "the Company")

**Interim Results
for the six months ended
30 June 2008**

Curidium Medica Plc (AIM: CUR), a pioneer of diagnostic technology for personalised medicine, is pleased to announce its interim results for the six months ended 30 June 2008.

Highlights

- Introduction of PsychINDx™ to major pharmaceutical companies
- Progress with Major Depression Programme in partnership with Takeda
- Increased business and product development
- Co-founder of the Company, Dr. Barry Porter appointed Chairman
- Operating loss £683,000 (2007: £553,000)
- Financial assets, cash and cash equivalents £3.6 million (2007:£1.3 million)

Commenting on the results, Dr. Barry Porter, Chairman of Curidium said:

"This has been an important period for the Company; we have had significant interest in our novel diagnostic tool PsychINDx™ from a number of leading pharmaceutical companies and we look forward to bringing these discussions to completion in the next year. Our partnership with Takeda continues to progress well and we expect to analyse our initial data in the second half of the year. Personalised medicine is growing in popularity as pharmaceutical companies see an opportunity to reduce development costs, and Curidium is well placed to take advantage of this in the field of CNS disorders."



For further information:

Curidium Medica plc

Barry Porter (Chairman)

+44 (0)20 7554 5100

Rob Smith (Finance Director)

+44 (0)20 7554 5102

<http://www.curidium.com/>

FinnCap

Charles Cunningham

+44 (0) 20 7600 1658

<http://www.jmfinncapitalmarkets.com/>

Media enquiries:

Abchurch

Heather Salmond / Stephanie Cuthbert/
Simone Alves

+44 (0) 20 7398 7700

stephanie.cuthbert@abchurch-group.com

www.abchurch-group.com



Chairman's Statement

During the first half of 2008 Curidium Medica introduced PsychINDx™, its diagnostic blood test to sub-classify patients with schizophrenia or bipolar disorder, to leading pharmaceutical companies in Europe and the United States. We have received positive feedback and there has been significant interest in our approach. The timing of revenue generating contracts will depend on the acceptance of Curidium's technology by drug developers and the phasing of their drug development programmes. As we continue to work towards these contracts we have embarked on a number of product development initiatives to strengthen PsychINDx™ and enhance its attractiveness to potential customers.

Our work in Major Depressive Disorder, in partnership with Takeda, is progressing well and we are currently applying our Homomatrix® technology to brain tissue samples recently sourced by the Company. The data analysis process will be carried out in the second half of 2008 with the generation of initial results in early 2009.

During the first half of the year, we increased our business and product development activities. This has resulted in a widening of our operating loss, however, we continue to manage cash resources carefully and the strength of our balance sheet is being deployed to optimise the Company's potential.

The exciting field of personalised medicine is evolving rapidly and Curidium is well placed to play a significant part in its developments, particularly as the regulators and pharmaceutical companies recognise its growing importance. We are currently reviewing our approach to the market and are refining our business strategy so that we can capitalise on the growing opportunities ahead and deliver the best possible return to share holders.

Dr. Barry Porter

Chairman

25th September 2008



CONSOLIDATED INCOME STATEMENT

For the six months ended 30 June 2008

	6 months to 30 June 2008 (unaudited) £000s	6 months to 30 June 2007 (unaudited) £000s	Year ended 31 December 2007 (audited) £000s
Research and Development	(249)	(177)	(390)
Administrative expenses	(434)	(379)	(906)
Other operating income	-	3	3
<i>(Loss) from operations</i>	<u>(683)</u>	<u>(553)</u>	<u>(1,293)</u>
Interest receivable	114	20	125
Loss on ordinary activities before tax	<u>(569)</u>	<u>(533)</u>	<u>(1,168)</u>
Tax	-	-	73
Loss for the period attributable to shareholders	<u>(569)</u>	<u>(533)</u>	<u>(1,095)</u>
	Pence	Pence	Pence
Loss per share, basic and diluted	3.00	3.13	5.94

The Group's operating losses arise from continuing operations.

There were no recognised gains or losses other than those recognised in the income statement above.



CONSOLIDATED BALANCE SHEET

As at 30 June 2008

	as at 30 June 2008 £000s	as at 30 June 2007 £000s	as at 31 December 2007 £000s
ASSETS			
Non-current assets			
Goodwill	1,098	1,098	1,098
Property, plant and equipment	7	7	7
	<hr/> 1,105	<hr/> 1,105	<hr/> 1,105
Current assets			
Trade and other receivables	260	93	304
Other Financial Assets	1,967	-	2,030
Cash and cash equivalents	1,654	1,291	2,128
	<hr/> 3,881	<hr/> 1,384	<hr/> 4,462
Total assets	<hr/> 4,986	<hr/> 2,489	<hr/> 5,567
Current liabilities			
Trade and other payables	(171)	(187)	(216)
	<hr/> (171)	<hr/> (187)	<hr/> (216)
Net current assets	<hr/> 3,710	<hr/> 1,197	<hr/> 4,246
Non-current liabilities	-	-	-
Total liabilities	<hr/> (171)	<hr/> (187)	<hr/> (216)
Net assets	<hr/> 4,815	<hr/> 2,302	<hr/> 5,351
EQUITY			
Share Capital	7,695	4,050	7,662
Accumulated deficit	(2,880)	(1,748)	(2,311)
Equity attributable to equity holders of the parent Company	<hr/> 4,815	<hr/> 2,302	<hr/> 5,351

CONSOLIDATED CASH FLOW INFORMATION

Summary Cash Flow Statement

	6 months to 30 June 2008 (unaudited) £000s	6 months to 30 June 2007 (unaudited) £000s	Year ended 31 December 2007 (audited) £000s
Operating activities			
Operating loss	(683)	(553)	(1,292)
Share based payments	34	124	145
Depreciation	2	2	2
Loss on disposal of property, plant and equipment	-	-	1
(Increase) / decrease in receivables	44	20	(118)
Increase / (decrease) in payables	(45)	(42)	(14)
Net cash outflow from operating activities	(648)	(449)	(1,276)
Investing activities			
Interest received	114	20	125
Purchases of property, plant and equipment	(3)	(3)	(4)
Deposits in fixed term bank accounts with maturity dates greater than three months	63	-	(2,030)
Net cash used in investing activities	174	17	(1,909)
Financing activities			
Proceeds from issue of share capital	-	-	3,590
Net cash from financing activities	-	-	3,590
Net increase/(decrease) in cash and cash equivalents	(474)	(432)	406
Cash and cash equivalents at beginning of period	2,128	1,723	1,722
Cash and cash equivalents at end of period	1,654	1,291	2,128



Notes to the interim statements

For the six months ended 30th June 2008

SIGNIFICANT ACCOUNTING POLICIES

Basis of Accounting

The financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS). The financial statements have been prepared on the historical cost basis. The principal accounting policies adopted are set out below and are consistent with those set out in the Company Annual Report and Accounts for the year ended 31st December 2007.

Basis of Consolidation

The consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company (its subsidiaries) made up to 30th June and 31st December each year. Control is achieved where the Company has the power to govern the financial and operating policies of an investee entity so as to obtain benefits from its activities.

On acquisition, the assets and liabilities and contingent liabilities of a subsidiary are measured at their fair values at the date of acquisition. Any excess of the cost of acquisition over the fair values of the identifiable net assets acquired is recognised as goodwill. Any deficiency of the cost of acquisition below the fair values of the identifiable net assets acquired (i.e. discount on acquisition) is credited to profit and loss in the period of acquisition. The interest of minority shareholders is stated at the minority's proportion of the fair values of the assets and liabilities recognised. Subsequently, any losses applicable to the minority interest in excess of the minority interest are allocated against the interests of the parent.

All intra-group transactions, balances, income and expenses are eliminated on consolidation.



On 5th July 2006 the shareholders approved the business combination of the Company and Curidium Limited, under the AIM rules and IFRS this transaction meets the criteria of a Reverse Takeover.

The consolidated financial statements prepared following the reverse are issued in the name of Curidium Medica plc, but they are a continuance of the financial statements of Curidium Limited. Therefore the assets and liabilities of Curidium Limited have been recognised and measured in these consolidated financial statements at their pre-combination carrying values. The retained earnings and other equity balances recognised in these consolidated financial statements are the retained earnings and other equity balances of Curidium Limited immediately before the business combination.

The amount recognised as issued equity instruments in these consolidated financial statements has been determined by adding the issued equity of Curidium Limited immediately before the business combination to the cost of the consideration. However, the equity structure appearing in these consolidated financial statements (the number and type of equity instruments issued) reflect the equity structure of Curidium Medica plc, including equity instruments issued by the Company to effect the consolidation.

Where necessary, adjustments are made to the financial statements of subsidiaries to bring the accounting policies used into line with those used by the Group.

Share-based Payments

The Group has applied the requirements of IFRS 2 Share-based Payments. In accordance with the transitional provisions, IFRS 2 has been applied to all grants of equity instruments after 7th November 2002 that were unvested as of 1st January 2005.

The Group issues equity-settled and cash-settled share-based payments to certain employees. Equity-settled share-based payments are measured at fair value at the date of grant. The fair value determined at the grant date of the equity-settled share-



based payments is expensed on a straight-line basis over the vesting period, based on the Group's estimate of shares that will eventually vest.

Fair value is measured by use of a binomial model. The expected life used in the model has been adjusted, based on management's best estimate, for the effects of non-transferability, exercise restrictions, and behavioural considerations.

A liability equal to the portion of the goods or services received is recognised at the current fair value determined at each balance sheet date for cash-settled share-based payments.

Share consolidation

On 7th March 2008, at an Extraordinary General Meeting, the members approved a 1 for 30 consolidation of the Company's ordinary share capital. Comparative loss per share data has been adjusted to reflect the revised issued share capital.

The interim report for the six months to 30th June 2008, which complies with IAS34, was approved by the Board on 25th September 2008.



LOSS PER SHARE

Loss per share data is based on the consolidated loss using reverse accounting principles and the adjusted weighted average number of shares in issue of the Parent Company.

	6 months to 30 June 2008 (unaudited)	6 months to 30 June 2007 (unaudited)	Year ended 31 December 2007 (audited)
	£	£	£
Loss for the purposes of basic and diluted loss per share being net loss attributable to equity holders of the parent	(569)	(533)	(1,095)

Number of shares

	6 months to 30 June 2008 (unaudited)	6 months to 30 June 2007 (unaudited)	Year ended 31 December 2007 (audited)
Adjusted weighted average number of ordinary shares for the purposes of basic and diluted earnings per share	18,943,439	17,036,125	18,449,457

The share options are anti-dilutive as they decrease the loss per share.

The denominators for the purposes of calculating both basic and diluted earnings per share have been adjusted to reflect the share consolidation completed in March 2008.



SHARE CAPITAL

Share Capital for Curidium Medica plc is set out in the following table:

	as at 30 June 2008 (unaudited) Number	as at 30 June 2007 (unaudited) Number	as at 31 December 2007 (audited) Number
Authorised:			
Ordinary shares of 0.1p each	-	860,000,000	860,000,000
Ordinary shares of 3p each	28,666,666	-	-
Deferred shares of 24p each	40,000,000	40,000,000	40,000,000
Deferred shares of 0.9p each	60,000,000	60,000,000	60,000,000
	128,666,666	960,000,000	960,000,000
Alloted, called up and fully paid:			
Ordinary shares of 0.1p each	-	457,811,392	568,303,195
Ordinary shares of 3p each	18,943,439	-	-
Deferred shares of 24p each	17,866,670	17,866,670	17,866,670
Deferred shares of 0.9p each	35,405,696	35,405,696	35,405,696
	72,215,805	511,083,758	621,575,561
	as at 30 June 2008 (unaudited) £000s	as at 30 June 2007 (unaudited) £000s	as at 31 December 2007 (audited) £000s
Authorised:			
Ordinary shares of 0.1p each	-	860	860
Ordinary shares of 3p each	860	-	-
Deferred shares of 24p each	9,600	9,600	9,600
Deferred shares of 0.9p each	540	540	540
	11,000	11,000	11,000
Alloted, called up and fully paid:			
Ordinary shares of 0.1p each	-	180	568
Ordinary shares of 3p each	568	-	-
Deferred shares of 24p each	4,288	4,288	4,288
Deferred shares of 0.9p each	319	319	319
	5,175	4,787	5,175



STATEMENT OF CHANGES IN EQUITY

	£000s
Balance as at 1 January 2007	5,351
Share consolidation adjustment	33
Net loss for the period	(569)
Balance at 30 June 2007	<hr/> 4,815

Equity comprises share capital, share premium and retained earnings.

UNAUDITED RESULTS

The unaudited results for period ended 30 June 2008 do not constitute statutory accounts within the meaning of Section 240 of the Companies Act 1985. The comparative figures for the year ended 31 December 2007 are extracted from the statutory financial statements which have been filed with the Registrar of Companies and which contain an unqualified audit report and did not contain statements under Section 237(2) or (3) of the Companies Act 1985.

COPIES OF INTERIM REPORT

The Interim report is available to view and download from the Companies website at www.curidium.com. If shareholders would like a hardcopy of the interim report they should contact the Company Secretary, Rob Smith, on 020 7554 5100.